Table 2.
Baseline characteristics of patients with a diagnosis of TG according to their archetype
| Characteristic | Archetype 1 n=68 | Archetype 2 n=47 | Archetype 3 n=122 | Archetype 4 n=56 | Archetype 5 n=92 | P Value |
|---|---|---|---|---|---|---|
| Recipient characteristics | ||||||
| Age (yr), mean (SD) | 43.45 (15.25) | 38.44 (15.67) | 46.45 (14.99) | 37.46 (16.19) | 47.76 (14.88) | <0.001 |
| Male, n (%) | 37 (54.41) | 33 (70.21) | 68 (55.74) | 35 (62.50) | 53 (57.61) | 0.42 |
| ESRD causes, n (%) | ||||||
| GN | 30 (44.12) | 19 (40.43) | 41 (33.61) | 30 (53.57) | 42 (45.65) | 0.12 |
| Diabetes | 8 (11.76) | 6 (12.77) | 16 (13.11) | 4 (7.14) | 4 (4.35) | 0.18 |
| Vascular | 4 (5.88) | 3 (6.38) | 5 (4.10) | 2 (3.57) | 6 (6.52) | 0.89 |
| Tubulo-interstitial | 11 (16.18) | 8 (17.02) | 31 (25.41) | 10 (17.86) | 24 (26.09) | 0.39 |
| Other | 3 (4.41) | 0 | 2 (1.64) | 3 (5.36) | 1 (1.09) | 0.23 |
| Unknown | 12 (17.65) | 11 (23.40) | 27 (22.13) | 7 (12.50) | 15 (16.30) | 0.49 |
| GN ESRD causes, n (%) | ||||||
| MPGN | 6 (20.00) | 6 (31.58) | 7 (17.07) | 4 (13.33) | 4 (9.52) | 0.39 |
| TMA | 4 (13.33) | 0 | 3 (7.32) | 2 (6.67) | 3 (7.14) | 0.52 |
| IgA nephropathy | 12 (40.00) | 5 (26.32) | 14 (34.15) | 11 (36.67) | 14 (33.33) | 0.51 |
| Lupus | 2 (6.67) | 2 (10.53) | 3 (7.32) | 2 (6.67) | 4 (9.52) | 0.91 |
| Membranous nephropathy | 0 | 0 | 3 (7.32) | 0 | 4 (9.52) | 0.22 |
| Alport | 1 (3.33) | 2 (10.53) | 1 (2.44) | 1 (3.33) | 3 (7.14) | 0.52 |
| Amyloidosis | 0 | 0 | 0 | 0 | 1 (2.38) | 0.68 |
| FSGS | 3 (10.00) | 3 (15.79) | 6 (14.63) | 3 (10.00) | 5 (11.90) | 0.99 |
| Crescent glomerulopathy | 2 (6.67) | 1 (5.26) | 1 (2.44) | 3 (10.00) | 2 (4.76) | 0.39 |
| Unspecified | 0 | 0 | 3 (7.32) | 4 (13.33) | 2 (4.76) | 0.11 |
| Positive serology at the time of transplant, n (%) | ||||||
| HCV | 7 (10.29) | 4 (8.51) | 10 (8.20) | 3 (5.36) | 11 (11.96) | 0.74 |
| HBV | 3 (4.48) | 2 (4.35) | 15 (12.71) | 2 (4.76) | 5 (5.43) | 0.20 |
| HIV | 0 | 0 | 0 | 1 (1.79) | 1 (1.09) | 0.38 |
| CMV | 41 (60.29) | 29 (63.04) | 80 (65.57) | 27 (50.94) | 61 (66.30) | 0.38 |
| Donor characteristics | ||||||
| Age (yr), mean (SD) | 43.52 (16.84) | 41.70 (18.40) | 53.08 (16.55) | 40.88 (16.41) | 48.79 (14.59) | <0.001 |
| Male, n (%) | 34 (50.75) | 20 (42.55) | 57 (47.50) | 30 (58.82) | 48 (52.75) | 0.53 |
| Creatinine (μmol/L), mean (SD) | 74.22 (30.50) | 76.11 (30.59) | 85.98 (52.96) | 83.50 (33.83) | 80.84 (36.24) | 0.47 |
| Deceased donor, n (%) | 42 (61.76) | 32 (68.09) | 99 (81.15) | 37 (66.07) | 73 (79.35) | 0.01 |
| Double transplantation, n (%) | 3 (4.41) | 2 (4.26) | 9 (7.38) | 1 (1.79) | 4 (4.35) | 0.66 |
| Positive serology, n (%) | ||||||
| Hepatitis C virus | 1 (1.59) | 1 (2.27) | 1 (0.85) | 0 | 1 (1.11) | 0.89 |
| Hepatitis B virus | 2 (3.12) | 1 (2.27) | 4 (3.39) | 0 | 3 (3.33) | 0.96 |
| HIV | 0 | 0 | 0 | 0 | 0 | >0.99 |
| CMV | 39 (57.35) | 22 (46.81) | 64 (52.46) | 34 (66.67) | 51 (56.04) | 0.34 |
| Transplant baseline characteristics | ||||||
| Prior kidney transplant, n (%) | 10 (14.71) | 5 (10.64) | 29 (23.77) | 6 (10.71) | 28 (30.43) | <0.01 |
| Cold ischemia time (h), mean (SD) | 12.88 (10.16) | 13.53 (8.84) | 16.91 (9.79) | 15.93 (12.04) | 16.49 (9.78) | 0.05 |
| Delayed graft function, n (%)a | 9 (13.24) | 11 (23.40) | 47 (38.52) | 12 (21.43) | 28 (30.43) | 0.003 |
| HLA A/B/DR mismatch, mean (SD), number | 3.50 (1.52) | 3.91 (1.43) | 3.41 (1.52) | 3.29 (1.33) | 3.41 (1.42) | 0.13 |
| Donor specific anti-HLA antibodies on d 0, n (%) | 10 (14.71) | 5 (10.64) | 22 (18.03) | 2 (3.57) | 25 (27.17) | 0.002 |
| Circulating anti-HLA DSA MFI, median (IQR) | 3396 (1129–9441) | 945 (868–1400) | 2479 (889–8736) | 2625 (2625–2625) | 3679 (858–15,106) | 0.52 |
| Treatments, n (%) | ||||||
| Steroids | 9 (14.06) | 18 (39.13) | 19 (16.96) | 6 (10.91) | 22 (25.00) | 0.004 |
| Anti-CD20 | 7 (10.94) | 12 (26.09) | 10 (8.93) | 5 (9.09) | 21 (24.14) | <0.01 |
| Plasma exchange | 6 (9.38) | 10 (22.22) | 12 (10.71) | 0 | 21 (23.86) | <0.001 |
| IVIG | 9 (14.06) | 18 (39.13) | 22 (19.47) | 10 (18.18) | 46 (52.17) | <0.001 |
| Eculizumab | 0 | 0 | 3 (2.68) | 0 | 4 (4.60) | 0.21 |
| Bortezomib | 0 | 0 | 0 | 0 | 4 | 0.02 |
| Centers | ||||||
| Edmonton | 34 (50.00) | 26 (55.32) | 26 (21.31) | 47 (83.93) | 29 (31.52) | |
| Paris | 34 (50.00) | 21 (44.68) | 96 (78.69) | 9 (16.07) | 63 (68.48) | <0.001 |
Fisher exact tests were conducted to compare proportions, and unpaired tests were conducted to compare continuous variables. HCV, hepatitis C virus; HBV, hepatitis B virus; CMV, Cytomegalovirus; HLA, human leukocyte antigen; DSA, donor-specific antibodies; IVIG, intravenous immunoglobulin.
a
Delayed graft function was defined as the use of dialysis in the first postoperative wk.